trastuzumab
Pronunciation: trass-TOO-zoo-mab
Other Name(s): Herceptin®; Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Appearance: Clear, colourless solution
mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Dec 2024
Eligibility Forms
Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer Trastuzumab (Biosimilar) - Advanced Gastric Gastroesophageal or Esophageal Cancer Trastuzumab Emtansine - Unresectable Locally Advanced or Metastatic Breast Cancer Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer Trastuzumab (Biosimilar) with Tucatinib and Capecitabine - Metastatic Breast Cancer Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast CancerPatient Info Sheet
Sep 2022
What it is used for
For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication. See our biosimilar pamphlet for more information.